Drugs / M0324
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07166601 | Oct 2025 → Feb 2029 expected | neoplasm | EMD Serono Research & Development Institute, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M0324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07166601 ↗ |
| Target | CD40 | “Bispecific (MUC-1 x CD40) Antibody” NCT07166601 ↗ |